Ostoform’s mission to improve quality of life for ostomy pouch users.
Ostoform was born out of a need to improve skin health and quality of life for people who have an ostomy. We have set ourselves the challenge of solving problems experienced by those who must regularly cope with appliance leaks and the discomfort of damaged peristomal skin.
Ostoform Seal with FLOWASSIST Protection launched in the US; Medline Industries Inc. Distribution confirmed.
Despite the many challenges presented by the global pandemic, it was a productive year for Ostoform with the commercialisation of the Ostoform Seal with FLOWASSIST Protection in several countries, including the United States. With the official commercialisation and an approved HCPCS code: A4385, it was announced that Ostoform would partner with Medline Inc. Industries for the distribution of the Ostoform product range nationally and across the continuum of care.
Ostoform technology recognised and supported with funding.
Ostoform’s commitment to developing ostomy products to improve the lives of ostomy pouch users was duly recognised this year when it was announced that Ostoform and partners would receive €2.67 million in funding through the Disruptive Technologies Innovation Fund, managed by the Department of Enterprise, Trade and Employment and Enterprise Ireland. This funding was allocated to further support the development of a completely unique material processing technology, along with the commercialisation of a range of novel medical products.
Third clinical study published 2021 detailing 71% longer wear-time and improved clinical outcomes.
In conjunction with product development, Ostoform continues to build certainty around the efficacy of the patented FLOWASSIST technology, both in ostomy care and in fistula management. In March of this year, Ostoform announced that Advances in Skin & Wound Care had published results of a third clinical study that evaluated the Ostoform Seal for individuals with an ileostomy. The positive data from this clinical study, combined with the results of earlier clinical studies, indicated a clear trend toward improvements in peristomal skin condition using the Ostoform Seal. This study also demonstrated a longer appliance wear-time with 71% of participants stating that the Ostoform Seal lasted longer than their current barrier ring. Furthermore, case studies carried out in Holland in relation to fistula management demonstrated improved clinical outcomes for this difficult to manage cohort.
Excited to attend WOCNext® 2021: Booth #V205.
Ostoform is excited to talk and listen to nurses and healthcare professionals, and to demonstrate the Ostoform Seal with FLOWASSIST Protection, albeit virtually, at booth #V205.
For more information visit www.ostoform.com or email us at firstname.lastname@example.org